Our most advanced lead is currently in phase 2 trials

Lead compound MAP4343

with Translational Biomarkers

Back-up molecules & new developments

CHU Bicêtre, Batiment Pincus, 80 rue du général Leclerc, 94270 Le Kremlin-Bicêtre, France.